Phase II study of S-1 for non-small lung cancer after failure of two or three prior chemotherapy regimens
Latest Information Update: 09 Aug 2016
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Aug 2016 Status changed from recruiting to discontinued.
- 09 May 2012 New trial record